A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of OratecanTM in Patients With Advanced Solid Cancer((Q1DX5/W)X2 for 3W).

Trial Profile

A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of OratecanTM in Patients With Advanced Solid Cancer((Q1DX5/W)X2 for 3W).

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2014

At a glance

  • Drugs Irinotecan (Primary) ; HM 30181A
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Oct 2014 Results published in a Kinex Pharmaceuticals media release.
    • 05 May 2014 According to a Kinex media release, the US FDA has allowed the IND application for Oratecan.
    • 05 Dec 2011 Planned End Date changed from 1 Feb 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top